Evidence map›Paper›PMID 9788977›Full record

Trial reportThe Journal of clinical investigation1998

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

N E Lane, S Sanchez, G W Modin, H K Genant, E Pierini, C D Arnaud

3 registry-linked trialsAbstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 120 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00004993 phase2completednot on this mapstarted 1999, after this paper: background citation

Can PTH Reverse Glucocorticoid-induced Osteoporosis

TypeinterventionalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran1999 to 2001ConditionsOsteoporosisArmsParathyroid hormone (hPTH 1-34)
NCT01400516 phase4completednot on this mapstarted 2011, after this paper: background citation

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

TypeinterventionalSponsorBrigham and Women's HospitalRan2011 to 2016Enrolled26ConditionsRheumatoid ArthritisArmsTeriparatide, calcium citrate, Vitamin D, TNF antagonist
NCT03396315 phase2completednot on this mapstarted 2018, after this paper: background citation

Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis

TypeinterventionalSponsorColumbia UniversityRan2018 to 2023Enrolled24ConditionsIOP, OsteoporosisArmsAlendronate, Zoledronic Acid
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007
    Pooled it
  7. Parathyroid hormone for the treatment of osteoporosis: a systematic review.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2006
    Pooled it
  8. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2006
    Guideline
  9. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013
    Trial
  10. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.The Journal of clinical endocrinology and metabolism · 2013
    Trial
  11. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2009
    Trial
  12. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007
    Trial
  13. Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2005
    Trial
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

N E LaneDepartment of Medicine, University of California at San Francisco, San Francisco, California 94143, USA. nelane@itsa.ucsf.edu
S Sanchez
G W Modin
H K Genant
E Pierini
C D Arnaud

Funding

PHS HHS 1-RO1-46661
6 · The paper itself

Abstract

Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (+/-SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35+/-5.5% and 11+/-1.4%, respectively, compared with a relatively small change of 1.7+/-1.8% and 0+/-0.9% in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5% for the lumbar spine by QCT (P < 0.001) and 9.8% for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150%, whereas markers of bone resorption increased only 100%, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid- induced osteoporosis who are taking hormone replacement.

Indexed as

Absorptiometry, PhotonAdrenal Cortex HormonesAgedAged, 80 and overBone DensityBone ResorptionCalcification, PhysiologicEstrogensFemaleHumansMiddle AgedOsteoporosisPostmenopauseSpinal FracturesTeriparatideTomographyAdrenal Cortex HormonesEstrogensTeriparatideNon-programmatic

Identifiers

PMID9788977
PMCPMC509014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.